BioSpace News Archive

Dynatronics Corporation today announced financial results for its fourth quarter and fiscal year ended June 30, 2020.

John M. Gay, Vice President, Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the launch of AlloCare at the CareDx organized AlloCare Transplant Festival on September 26, 2020.

IncellDx, Inc., a global leader in single-cell diagnostics, announces the USPTO has issued patent US10,782,298 to IncellDx.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations, provides clarification on how registered shareholders or duly appointed proxyholders who plan to attend the Company’s virtual Annual General and Special Meeting at 4:30pm EDT can cast their vote at the Meeting.

Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations, announced that McGill University Health Centre has re-commenced new patient enrollment and treatment in the Company’s Phase II Non-Muscle Invasive Bladder Cancer clinical study.

Grant s Suppor t Community Engagement for Patient Advocacy Organization s Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1 3 th , 2020 SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the third annual Cytokinetics Communications Fellowship Grant program. The Communications Fellowship program provides a total of $100,000 in gran

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today announced that written guidance from the U.S. Food and Drug Administration (FDA) enable

Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will participate in a panel discussion at the upcoming Stifel Immunology & Inflammation Summit on Thursday, October 1, 2020 at 3:00 p.m. ET.

Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced that NEXPLANON® 68 mg, a hormonal contraceptive implant, is now available in Canada.1 The implant, approved by Health Canada for the prevention of pregnancy for up to three years, provides Canadians with a progestin-only contraceptive option that is long-acting.1